The U.S. Food and Drug Administration is moving toward allowing compounding pharmacies to produce more than a dozen injectable peptides that were banned because of potentially significant safety risks, the New York The Peptide Split: How GLP 1s, Lutathera, Vosoritide, and Peptide Cancer Vaccines Are Quietly Rewriting Medicine While BPC 157, TB 500, MOTS c, and the Wellness Grift Borrow Their Halo FDA mulls compounding for peptides previously flagged over safety risks BioSpace FDA Issues Warning: Compounding Certain Bulk Drug Substances May Pose Major Legal and Patient Safety Risks Lengea